Ucello Therapeutics, a San Diego, CA and Chengdu, China-based biotechnology company developing universal CAR-T therapies, raised US$25M in Series A funding.
The round was led by Matrix Partners China with participation form Co-Win Ventures, Northern Light Venture Capital, and Elikon Venture. Also joining the round was existing angle investor Chengdu Bio-town Fund.
The company intends to use the funds to advance development of proprietary universal CAR-T technology platform CBT-X20, progress pipeline programs including lead asset AT19 through to US and China IND filings, and build a state of the art GMP-ready clinical manufacturing facilities.
Led by CEO Dr. Qiang Zou, Ucello is a biotechnology company focused on the development of allogeneic cell therapies. Powered by its proprietary universal CAR-T cell technology platform CBT-X20, Ucello has developed several “off-the-shelf” cell therapy pipelines for the treatment of solid tumors and hematologic malignancies, and potentially change the landscape of CAR-T cell therapy.
FinSMEs
14/02/2022